Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer by Pedro Nazareth Aguiar Jr., Carmélia Maria Noia Barreto, Bárbara de Souza Gutierres, Hakaru Tadokoro, Gilberto de Lima Lopes Jr

Get full text

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer by Marcos Aurélio Fonseca Magalhães Filho, Pedro Nazareth Aguiar Jr., Milena Brachmans Mascarenhas Neves, Gilberto de Lima Lopes Jr., Auro del Giglio

Get full text

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer by Pedro Nazareth Aguiar Jr., Pui San Tan, Sarah Simko, Carmelia Maria Noia Barreto, Bárbara de Souza Gutierres, Auro del Giglio, Gilberto de Lima Lopes Jr

Get full text

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors by Mariane Teodoro Fernandes, Jacob J Adashek, Carmelia Maria Noia Barreto, Ana Cláudia Barbin Spinosa, Barbara de Souza Gutierres, Gilberto Lopes, Auro del Giglio, Pedro Nazareth Aguiar Jr

Get full text